Direct Biologics Reports Compelling Results From Phase 2 Trial With ExoFlo in Hospitalized Patients With Respiratory Failure or Moderate-to-Severe Acute Respiratory Distress Syndrome Due to COVID-19
| ARDSDelisted Stock | USD 0.27 0.02 8.00% |
Slightly above 55% of Aridis Pharmaceuticals' private investors are presently thinking to get in. The analysis of overall sentiment of trading Aridis Pharmaceuticals pink sheet suggests that some investors are interested at this time. Aridis Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Aridis Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Aridis Pharmaceuticals pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Aridis daily returns and investor perception about the current price of Aridis Pharmaceuticals as well as its diversification or hedging effects on your existing portfolios.
Aridis |
AUSTIN, Texas, March 14, 2023--Direct Biologics, LLC, a late-stage biotechnology company leveraging its regenerative medicine platform using extracellular vesicles derived from bone marrow mesenchymal stem cells to address multiple disease indications, announced favorable safety, dosing and efficacy results from its Phase 2 clinical trial of ExoFlo in hospitalized adult COVID-19 patients with moderate-to-severe acute respiratory distress syndrome .
Read at finance.yahoo.com
 |
Aridis Pharmaceuticals Fundamental Analysis
We analyze Aridis Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aridis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aridis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Earning
Price To Earning Comparative Analysis
Aridis Pharmaceuticals is currently under evaluation in price to earning category among its peers. Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Aridis Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aridis Pharmaceuticals pink sheet to make a market-neutral strategy. Peer analysis of Aridis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aridis Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Aridis Pharmaceuticals Related Equities
| RVPH | Reviva Pharmaceuticals | 8.77 | ||||
| AKTX | Akari Therapeutics | 8.04 | ||||
| ADTX | Aditxt | 6.06 | ||||
| ATXI | Avenue Therapeutics | 4.37 | ||||
| ABVC | ABVC Biopharma | 3.92 | ||||
| RNAZ | Transcode Therapeutics | 2.94 | ||||
| DRMA | Dermata Therapeutics | 2.73 | ||||
| KOD | Kodiak Sciences | 1.83 | ||||
| UNCY | Unicycive Therapeutics | 1.47 | ||||
| REVB | Revelation Biosciences | 1.33 | ||||
| HOTH | Hoth Therapeutics | 1.20 | ||||
| NRBO | Neurobo Pharmaceuticals | 0.43 | ||||
| CGTX | Cognition Therapeutics | 2.44 | ||||
| ZVSA | ZyVersa Therapeutics | 3.60 | ||||
| RVPHW | Reviva Pharmaceuticals | 4.35 | ||||
| VRAX | Virax Biolabs | 4.83 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Consideration for investing in Aridis Pink Sheet
If you are still planning to invest in Aridis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aridis Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |